ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 099

Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

Omkar Phadke1, Sampath Prahalad 2 and Kelly Rouster-Stevens 3, 1EMORY, Atlanta, Georgia, 2Emory + Children's Pediatric Institute, Atlanta, 3Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Anakinra, MAS, Tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: Treatment for systemic JIA (sJIA) complicated by macrophage activation syndrome (MAS) may involve blockade of IL-1 and IL-6. There are reports of adults with rheumatoid arthritis treated with anakinra and canakinumab who developed hepatotoxicity from IL-blockade exposure. There is a paucity of literature in pediatric patients

Methods: Retrospective chart review of patients with systemic JIA and MAS who received IL-1 or IL-6 blockade was performed. Patients with elevated transaminases and GGT after initiation of interleukin blockade were included

Results: We present 3 patients with sJIA/MAS who improved on anakinra or tocilizumab but developed markedly elevated transaminases/GGT shortly after IL-blocker initiation. Work-up for infectious and autoimmune hepatitis were negative in all patients.

#1: 13 year old female presented with fever, rash, polyarthritis, ferritin 47000 ng/ml, ALT 48 U/L, AST 197 U/L, GGT 62 U/L; sJIA/MAS was diagnosed. She started IV pulse steroids and anakinra 4 mg/kg/day, discharged on anakinra 8 mg/kg/day with improvement of all labs. One month later, ferritin normalized, while transaminases increased (ALT 1362; AST 645; GGT 341). Anakinra was stopped. Liver biopsy showed nonspecific mixed inflammation concerning for drug induced injury. Four weeks later, ALT fell to 38 and AST to 148 supporting drug induced hepatotoxicity. She has not had any recurrence of elevated transaminases/GGT after 6 months of canakinumab .

#2: 16 year old male with refractory sJIA/MAS previously on multiple medications (anakinra, canakinumab, tocilizumab, rilonacept). Anakinra 9.9 mg/kg/day was restarted for a sJIA flare. Transaminases rapidly increased with peak ALT 2492, AST 1673, GGT 219. Ferritin and cell counts were unchanged. Liver biopsy suggested drug induced hepatotoxicity. Anakinra was stopped. One month later, ALT/AST/GGT had normalized. He has been on Tofacitinib without transaminitis or active sJIA/MAS.

 #3: 2 year old male with sJIA (without MAS at presentation) initially on anakinra 4 mg/kg/day did well clinically but developed hepatitis (ALT 336, AST 129, GGT 16); Anakinra was stopped. Given continued sJIA disease activity and evolution of MAS, he started tocilizumab infusions (12 mg/kg every 2 weeks). His ferritin and cell counts improved, while ALT increased to 1388, AST to 2146, and GGT to 111. Tocilizumab was stopped. Liver biopsy was deferred given marked and rapid improvement in transaminases/GGT over the next week. Over the next 2 weeks his transaminases/GGT normalized. He is currently being transitioned to tofacitinib

Conclusion: The reversible hepatotoxic nature of anakinra and tocilizumab have been described in adults; we describe 3 similar pediatric cases. Clinicians should be cautious as IL-1 and IL-6 blockade is being used more frequently in sJIA. There should be a low index of suspicion for drug induced hepatotoxicity in cases of elevated transaminases/GGT, particularly if a patient has clinically improved


Disclosure: O. Phadke, None; S. Prahalad, None; K. Rouster-Stevens, None.

To cite this abstract in AMA style:

Phadke O, Prahalad S, Rouster-Stevens K. Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/reversible-hepatotoxicity-to-il-1-il-6-blockade-in-pediatric-patients-with-systemic-juvenile-idiopathic-arthritis-and-macrophage-activation-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reversible-hepatotoxicity-to-il-1-il-6-blockade-in-pediatric-patients-with-systemic-juvenile-idiopathic-arthritis-and-macrophage-activation-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology